Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06295731
Title INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS>=20 HNSCC (HexAgon-HN)
Acronym HexAgon-HN
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Inhibrx Biosciences, Inc
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
City of Hope Medical Center RECRUITING Duarte California 91010 United States Details
Los Angeles Cancer Network (LACN) RECRUITING Los Angeles California 91204 United States Details
Sutter Health RECRUITING Sacramento California 95816 United States Details
Sarcoma Oncology Center RECRUITING Santa Monica California 90403 United States Details
The Oncology Institute of Hope & Innovation RECRUITING Miami Florida 33169 United States Details
Mid Florida Hematology and Oncology Center RECRUITING Orange City Florida 32763 United States Details
Norton Cancer Institute RECRUITING Louisville Kentucky 40202 United States Details
Massachusetts General Hospital RECRUITING Boston Massachusetts 02114 United States Details
Karmanos Cancer Institute RECRUITING Detroit Michigan 48201 United States Details
Washington University St. Louis RECRUITING Saint Louis Missouri 63110 United States Details
Intermountain Health, St. Vincent Regional Hospital, Cancer Centers of Montana RECRUITING Billings Montana 59102 United States Details
Oncology Hematology West, PC dba Nebraska Cancer Specialists RECRUITING Omaha Nebraska 68130 United States Details
Christus St. Vincent Regional Cancer Center RECRUITING Santa Fe New Mexico 87505 United States Details
CHRISTUS Spohn Cancer Center RECRUITING Corpus Christi Texas 78404 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field